Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

View the full release here: https ... The ideal drive for a wide range of server applications such as AI, HPC, OLTP, cloud services and edge computing,DC3000MEis engineered to meet strict ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Delhi's Directorate of Education reveals the 2025-26 academic calendar. Summer break for government and aided schools starts May 11, ending June 30, 2025. The 51-day holiday offers students and ...